Klinik für Hämatologie, Onkologie und Palliativmedizin

Publikationen und Studien

Bücherregal

Studien "Solide Tumore"

  • PARLIM:  Panitumumab after Resection of Liver Metastases from Colorectal Cancer in KRAS Wild-type Patients
  • QoLiTrap
  • RENAISSANCE / FLOT5: Effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of AIO/CAO-V/CAOGI
  • CONKO-007: Randomisierte Phase-III-Studie zum Stellenwert einer Radiochemotherapie nach Induktionschemotherapie beim lokal begrenzten, inoperablen Pankreaskarzinom:Chemotherapie gefolgt von Radiochemotherapie im Vergleich zur alleinigen Chemotherapie
  • ELDORANDO: A randomized phase II study comparing pembrolizumab with methotrexate in elderly, frail or cisplatin-ineligible patients with head and neck cancers
  • ADRISK: Postoperative adjuvant radio chemo therapy (aRCH) with Cisplatin © versus aRCH with C and Pembrolizumab (P) in locally advanced head and neck squamous cell carcinoma (HNSCC); multicenter randomized Phase II study within the German interdisciplinary study group of German Cancer Society (IAG KHT); Pembro-Adjuvant-highRisk
  • HANNA: Eine nationale, prospektive, nicht-interventionelle Studie (NIS) mit Nivolumab (BMS-936558) bei Patienten mit Plattenepithelkarzinomen im Kopf-Hals-Bereich, die eine Tumorprogression während oder nach einer platinbasierten Therapie aufweisen.
  • OPTIM: A randomized phase II study on the OPTimization of Imunotherapy in squamous carcinoma of the head and neck
  • Eisai E7080-G000-307 CLEAR: a multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of Lenvatinib in combination with Everolimus or Pembrolizumab versus Sunitinib alone in First-Line Treatment of subjects with advanced renal cell carcinoma
  • STRONG: An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies (STRONG) Module A – Post-Chemotherapy Urothelial and NonUrothelial Carcinoma of the Urinary Tract
  • BMSCA209-274: A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma
  • SCOPE: Nicht-interventionelle Studie zur Untersuchung des Einflusses der Vorbehandlung vor der Verabreichung von Cabzitaxel auf das Behandlungsergebnis bei Patienten mit metastasiertem kastrationsresistentem Prostatakarzinom
  • COSS Register
  • IAWS 1/2-Register Studie:   A cooperative investigation of the Interdisciplinary German Sarcoma group (AIO/ARO/CAO) and the pediatric sarcoma group (CWS) to optimize either neo- or adjuvant treatment strategies for pediatric an d adult pts wth large sized, high grade non-rhabdomyo(soft tissu) sarcoma (NRSTS)
  • Yonsar: Nichtinterventionelle Studie zur Wirksamkeit und Sicherheit von Trabectedin (Yondelis®) bei Patienten mit fortgeschrittenem Weichteilsarkom
  • BMSCA209-592: An Exploratory Study of the Biologic Effects and Biomarkers of Nivolumab in combination with Ipilimumab in Subjects with Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer
  • PETRARCA: FLOT vs. FLOT/Herceptin/Pertuzumab for perioperative therapy of locally advanced esophagogastric adenocarcinoma expressing HER2, a phase II/III trial of the AIO
  • NEPAFOX: Randomisierte multizentrische Phase II/III Studie mit adjuvantem Gemcitabin versus neoadjuvant/adjuvantem FOLFIRINOX bei resektablem Pankreaskarzinom
  • SOCCER: Untersuchung zur Symptomkontrolle bei Pat. mit rez. und/oder met. SCCHN unter Erstlinientherapie mit Erbitux
  • TPExtreme AIO-KHT-0314: Randomisierte, kontrollierte Prüfung von Platin/Cetuximab in Kombination mit Docetaxel (TPEx) oder 5-FU (EXTREME) bei Patienten mit rezidivierenden/metastasierenden Plattenepithelkarzinomen im Kopf/Hals-Bereich
  • PAZOREAL: Prospektive, nicht-interventionelle Studie zur Untersuchung der Effizienz und Sicherheit von Pazopanib und Everolimus im Real-Life Setting bei fortgeschrittenem Nierenzellkarzinom in einer wachsenden Therapieumgebung.

Siehe auch Stuttgarter Cancer Center (SCC)

Studien "Hämatologische Systemerkrankung"

  • GMALL-Register: GMALL-Register u. Biomaterialbank
  • GMALL 08/2013: Therapieoptimierung bei erwachsenen Patienten mit neu diagnostizierter akuter lymphatischer Leukämie (ALL) oder lymphoblastischem Lymphom (LBL) durch individualisierte, gezielte und intensivierte Therapie; eine Phase IV-Studie mit einem Phase III-Teil zur Evaluation der Sicherheit und Wirksamkeit von Nelarabin bei T-ALL
  • BIO-Register
  • AMLSG 21-13: Randomized Phase III Study of Intensive Chemotherapy with or without Dasatinib (Sprycel™) in Adult Patients with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)
  • iVAC-L-CLL01: Patient-individualized peptide vaccination in combination with lenalidomide after first line therapy of CLL
  • HD 21: Therapieoptimierungsstudie (randomisierte Phase III-Studie) für Patienten mit Erstdiagnose eines fortgeschrittenen klassischen Hodgkin Lymphoms.
  • NIVEAU: Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to Gemcitabine, Oxaliplatin plus Rituximab in case of CD20+ Disease, - - DSHNHL 2015-1
  • PIX in DLBCL: firstline    R-CPOP as first line therapy for elderly patients with DLBCL and for patients with limited cardiac function with DLBCL
  • MATRix: Hochdosis-Chemotherapie und autologe Stammzelltransplantation oder konventionelle Chemotherapie als Konsolidierung bei primären ZNS-Lymphomen – randomisierte, kontrollierte, offene, multizentrische Phase III Studie mit 2 parallelen Armen
  • MARTA: Multizentrische Phase II-Studie zur altersadaptierten Hochdosistherapie gefolgt von autologer Stammzelltransplantation bei fitten älteren >  Jahren mit primär zerebralem Lymphom
  • TRIANGLE: Autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a European MCL network study
  • Marginalzonen-Lymphom-Register: Nicht-interventionelles prospektives Register zu Epidemiologie und Behandlungspraxis bei Marginalzonenlymphomen
  • OLYMP-1: Obinutuzumab in Marginal Zone Lymphoma
  • PTLD Register: Nichtinterventionelle, prospektive Registerstudie zur Behandlungspraxis der PTLD in der klinischen Routine (Deutschland 2006-2010)
  • PTLD-2: Risk-stratified sequential treatment of post-transplant lymphoproliferative diseases with 4 courses of rituximab SC followed by 4 courses of rituximab SC, 4 cources of rituximab SC combined with CHOP-21 or 4 courses of rituximab SC combined with alternating CHOP-21 and DHAOx
  • AMLSG 09-09: Phase III Studie zu Chemotherapie in Kombination mit All-Trans Retinsäure (ATRA) mit oder ohne Gemtuzumab Ozogamicin bei Patienten mit Akuter Myeloischer Leukämie (AML) und Mutation im Nucleophosmin 1 (NPM1) Gen (AMLSG 09-09)
  • AMLSG 16-10: Phase II Studie zu Middostaurin in der Induktions-, Konsolidierungs- u. Erhaltungstherapie sowie nach allogener Blutstammzelltransplantation bei Patienten mit neu diagnostizierter akuter myeloischer Leukämie und Nachweis einer internen Tandemduplikation des FTL§-Gens
  • RATIFY: Randomisierte, doppelt-blind Phase-III einer Induktions- und Konsilidierungs-Therapie+Midostaurin oder Placebo in Patienten mit neu diagnostizierter FLT3 mutierter AML, die jünger als 60 Jahre sind
  • HD 17: Therapieoptimierungsstudie in der Primärtherapie des intermediären Hodgkin Lymphoms: Therapiestratifizierung mittels FDG-PET
  • HD 18: Primärtherapie, fortgeschritt. Stadien
  • NIVAHL: Nivolumab and AVD in early-stage unfavourable classical Hodgkin Lymphoma: A GHSG randomized, multicenter phase II trial
  • MARiTA: Pilot study for a phase II trial to evaluate high-dose chemotherapy and autologous stem cell transplant in primary CNS lymphoma patients > 65 years
  • DSMMXIV: Lenalidomide, Adriamycin, Dexamethasone (RAD)versusLenalidomide, Bortezomib, Dexamethasone (VRD)For Induction in Newly Diagnosed Multiple Myeloma followed by Response-adapted Consolidation and Lenalidomide Maintenance - A Randomized Multicenter Phase III Trial

Siehe auch Stuttgarter Cancer Center (SCC)

Publikationen 2019

Schmitt AM, Herbrand AK, Fox CP, Bakunina K, Bromberg JEC, Cwynarski K, Doorduijn JK, Ferreri AJM, Illerhaus G, Issa S, Schorb E, Zucca E, Hemkens LG, Schandelmaier S, Kasenda B.
Rituximab in primary central nervous system lymphoma-A systematic review and meta-analysis
Hematol Oncol. 2019 Aug

 Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIO Investigators
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomized, phase 2/3 trial
Lancet. 2019 May

 
Schorb E, Finke J, Ihorst G, Kasenda B, Fricker H, Illerhaus G.
Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients
BMC Cancer. 2019 Mar

 
Schorb E, Illerhaus G, Finke J.
Current Treatment Standards in PCNSL
Dtsch Med Wochenschr. 2019 Feb

 
Kasenda B, Illerhaus G.
CNS border posts against rituximab?
Lancet Oncol. 2019 Jan

Publikationen 2018

von Baumgarten L, Illerhaus G, Korfel A, Schlegel U, Deckert M, Dreyling M.
The Diagnosis and Treatment of Primary CNS Lymphoma
Dtsch Arztebl Int. 2018 Jun

Brandt A, Matschke J, Fehrle W, von Wenserski L, Bokemeyer C, Illerhaus G, Binder M.
A significant proportion of patients with primary central nervous system lymphoma harbor clonal bone marrow B-cells
Leuk Lymphoma. 2018 Jul

Illerhaus G, Schorb E, Kasenda B.
Novel agents for primary central nervous system lymphoma: evidence and perspectives
Blood. 2018 Aug

Thurner L, Preuss KD, Bewarder M, Kemele M, Fadle N, Regitz E, Altmeyer S, Schormann C, Poeschel V, Ziepert M, Walter S, Roth P, Weller M, Szczepanowski M, Klapper W, Monoranu C, Rosenwald A, Möller P, Hartmann S, Hansmann ML, Mackensen A, Schäfer H, Schorb E, Illerhaus G, Buslei R, Bohle RM, Stilgenbauer S, Kim YJ, Pfreundschuh M.
Hyper N-glycosylated SAMD14 and neurabin-I as driver CNS autoantigens of PCNSL
Blood. 2018 Sep

Publikationen 2017

Fritsch K, Kasenda B, Schorb E, Hau P, Bloehdorn J, Möhle R, Löw S, Binder M, Atta J, Keller U, Wolf HH, Krause SW, Heß G, Naumann R, Sasse S, Hirt C, Lamprecht M, Martens U, Morgner A, Panse J, Frickhofen N, Röth A, Hader C, Deckert M, Fricker H, Ihorst G, Finke J, Illerhaus G.
High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study).
Leukemia. 2017 Apr;31(4):846-852.

Laquente B, Lopez-Martin J, Richards D, Illerhaus G, Chang DZ, Kim G, Stella P, Richel D, Szcylik C, Cascinu S, Frassineti GL, Ciuleanu T, Hurt K, Hynes S, Lin J, Lin AB, Von Hoff D, Calvo E.
A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients.
BMC Cancer. 2017 Feb 15;17(1):137.

Schorb E, Fox CP, Fritsch K, Isbell L, Neubauer A, Tzalavras A, Witherall R, Choquet S, Kuittinen O, De-Silva D, Cwynarski K, Houillier C, Hoang-Xuan K, Touitou V, Cassoux N, Marolleau JP, Tamburini J, Houot R, Delwail V, Illerhaus G, Soussain C, Kasenda B.
High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study.
Bone Marrow Transplant. 2017 Aug;52(8):1113-1119.

Al-Batran SE, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, Schmalenberg H, Luley KB, Prasnikar N, Egger M, Probst S, Messmann H, Moehler M, Fischbach W, Hartmann JT, Mayer F, Höffkes HG, Koenigsmann M, Arnold D, Kraus TW, Grimm K, Berkhoff S, Post S, Jäger E, Bechstein W, Ronellenfitsch U, Mönig S, Hofheinz RD.
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
JAMA Oncol. 2017 Sep 1;3(9):1237-1244

Kasenda B, Ihorst G, Schroers R, Korfel A, Schmidt-Wolf I, Egerer G, von Baumgarten L, Röth A, Bloehdorn J, Möhle R, Binder M, Keller U, Lamprecht M, Pfreundschuh M, Valk E, Fricker H, Schorb E, Fritsch K, Finke J, Illerhaus G.
High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group.
Leukemia. 2017 Dec;31(12):2623-2629.   

Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosée P, Binder M, Fabbri A, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway C, Johnson P, Linton KM, Pukrop T, Sønderskov Gørløv J, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M, Deckert M, Politi LS, Finke J, Reni M, Cavalli F, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG).
Whole-brain radiotherapy or autologous stem-cell transplantation as consilodation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 3 trial.
Lancet Haematol. 2017 Nov;4(11):e510-e523.

Publikationen 2016

Fritsch K, Kasenda B, Schorb E, Hau P, Bloehdorn J, Möhle R, Löw S, Binder M, Atta J, Keller U, Wolf HH, Krause SW, Heß G, Naumann R, Sasse S, Hirt C, Lamprecht M, Martens U, Morgner A, Panse J, Frickhofen N, Röth A, Hader C, Deckert M, Fricker H, Ihorst G, Finke J, Illerhaus G.
High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study).
Leukemia. 2016 Dec

Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, Meiler J, Homann N, Lorenzen S, Schmalenberg H, Probst S, Koenigsmann M, Egger M, Prasnikar N, Caca K, Trojan J, Martens UM, Block A, Fischbach W, Mahlberg R, Clemens M, Illerhaus G, Zirlik K, Behringer DM, Schmiegel W, Pohl M, Heike M, Ronellenfitsch U, Schuler M, Bechstein WO, Königsrainer A, Gaiser T, Schirmacher P, Hozaeel W, Reichart A, Goetze TO, Sievert M, Jäger E, Mönig S, Tannapfel A.
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus prirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-lable, randomised phase 2/3 trial.
Lancet Oncol. 2016 Dec

Gerald Illerhaus, Benjamin Kasenda, Gabriele Ihorst, Gerlinde Egerer, Monika Lamprecht, Ulrich Keller, Hans-Heinrich Wolf, Carsten Hirt, Stephan Stilgenbauer, Mascha Binder, Peter Hau, Matthias Edinger, Norbert Frickhofen, Martin Bentz, Robert Möhle, Alexander Röth, Michael Pfreundschuh, Louisa von Baumgarten, Martina Deckert, Claudia Hader, Heidi Fricker, Elke Valk, Elisabeth Schorb, Kristina Fritsch, Jürgen Finke
High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS-lymphoma: a prospective, single-arm, phase 2 trial
Lancet Haematology 2016 Jul
   
Vitolo U, Seymour JF, Martelli M, Illerhaus G, Illidge T, Zucca E, Campo E, Ladetto M; ESMO Guidelines Committee
Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol. 2016 Jul 4

Kasenda B, Loeffler J, Illerhaus G, Ferreri AJ, Rubenstein J, Batchelor TT
The role of whole brain radiation in primary CNS lymphoma.
Blood. 2016 Jul 7

Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG).
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Lancet Haematol. 2016 May

Schorb E, Finke J, Ferreri AJ, Ihorst G, Mikesch K, Kasenda B, Fritsch K, Fricker H, Burger E, Grishina O, Valk E, Zucca E, Illerhaus G.
High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma-a randomized phase III trial (MATRix).
BMC Cancer. 2016 Apr 21

Ferreri AJ, Illerhaus G.
The role of autologous stem cell transplantation in primary CNS lymphoma.
Blood. 2016 Feb 1

Chapuy B, Roemer MG, Stewart C, Tan Y, Abo RP, Zhang L, Dunford AJ, Meredith DM, Thorner AR, Jordanova ES, Liu G, Feuerhake F, Ducar MD, Illerhaus G, Gusenleitner D, Linden EA, Sun HH, Homer H, Aono M, Pinkus GS, Ligon AH, Ligon KL, Ferry JA, Freeman GJ, van Hummelen P, Golub TR, Getz G, Rodig SJ, de Jong D, Monti S, Shipp MA.
Targetable genetic features of primary testicular and primary central nervous system lymphomas.
Blood. 2016 Feb 18

Publikationen 2015

Spies E, Fichtner M, Müller F, Krasemann S, Illerhaus G, Glatzel M, Binder M, Trepel M.
Comment on "Primary Central Nervous System (CNS) Lymphoma B Cell Receptors Recognize CNS Proteins".
J Immunol. 2015 Nov 15

Stein A, Atanackovic D, Hildebrandt B, Stübs P, Brugger W, Hapke G, Steffens CC, Illerhaus G, Bluemner E, Stöhlmacher J, Bokemeyer C.                                                                           
Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectalcancer.         
Br J Cancer. 2015 Sep

Haaß W, Kleiner H, Weiß C, Haferlach C, Schlegelberger B, Müller MC, Hehlmann R, Hofmann WK, Fabarius A, Seifarth W; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; German CML Study Group, Illerhaus G Collaborator                                            
Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy.                             
PLoS One. 2015 Jun

Illerhaus G.
III. Curent concepts  in primary central nervous lymphoma.
Hematol Oncol. 2015 Jun

O'Neill A, Mikesch K, Fritsch K, Kasenda B, Banerjee L, Burns F, Zakout G, Johnston R, Illerhaus G, Cwynarski K.
Outcomes for HIV-positive patients with primary central nervous system lymphoma after high-dose chemotherapy and auto-SCT.
Bone Marrow Transplant. 2015 Apr 13

Kasenda B, Schorb E, Fritsch K, Finke J, Illerhaus G.
Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS Lymphoma – a long-term follow-up study.
Ann Oncol. 2015 Mar

Kasenda B, Ferreri AJ, Marturano E, Forst D, Bromberg J, Ghesquieres H, Ferlay C, Blay JY, Hoang-Xuan K, Pulczynski EJ, Fosså A, Okoshi Y, Chiba S, Fritsch K, Omuro A, O'Neill BP, Bairey O, Schandelmaier S, Gloy V, Bhatnagar N, Haug S, Rahner S, Batchelor TT, Illerhaus G, Briel M.
First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)-a systematic review and individual patient data meta-analysis.
Ann Oncol. 2015 Feb

Hoffknecht P, Tufman A, Wehler T, Pelzer T, Wiewrodt R, Schütz M, Serke M, Stöhlmacher-Williams J, Märten A, Maria Huber R, Dickgreber NJ; Afatinib Compassionate Use Consortium (ACUC), Illerhaus G Collaborator
Efficacy of the irreversible ErbB family blocker afitinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.
J Thorac Oncol. 2015 Jan

Publikationen 2014

Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.
Schuler M, Fischer JR, Grohé C, Gütz S, Thomas M, Kimmich M, Schneider CP, Laack E, Märten A; Afatinib Compassionate Use Consortium.
Oncologist. 2014 Oct;19(10):1100-9. doi: 10.1634/theoncologist.2014-0103. Epub 2014 Sep 17.

The trabectome as treatment option in secondary glaucoma due to intraocular lymphoma.
van Oterendorp C, Ness T, Illerhaus G, Neuburger M, Jordan JF.
J Glaucoma. 2014 Sep;23(7):482-4. doi: 10.1097/IJG.0b013e31827a0875.

Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.
Proetel U, Pletsch N, Lauseker M, Müller MC, Hanfstein B, Krause SW, Kalmanti L, Schreiber A, Heim D, Baerlocher GM, Hofmann WK, Lange E, Einsele H, Wernli M, Kremers S, Schlag R, Müller L, Hänel M, Link H, Hertenstein B, Pfirrman M, Hochhaus A, Hasford J, Hehlmann R, Saußele S; German Chronic Myeloid Leukemia Study Group; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK).

Impact of neoadjuvant chemotherapy with PELF-protocoll versus surgery alone in the treatment of advanced gastric carcinoma.
Ruf C, Thomusch O, Goos M, Makowiec F, Illerhaus G, Ruf G.
BMC Surg. 2014 Jan 24;14:5. doi: 10.1186/1471-2482-14-5.

Publikationen 2013

Illerhaus G:
Primäre ZNS-Lymphome. Dtsch Med Wochenschr. 2013 Dec; 138(49):2515-8

Doolittle ND, Korfel A, Lubow MA, Schorb E, Schlegel U, Rogowski S, Fu R, Dósa E, Illerhaus G, Kraemer DF, Muldoon LL, Calabrese P, Hedrick N, Tyson RM, Jahnke K, Maron LM, Butler RW, Neuwelt EA:
Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma. Neurology 2013 Jul 2; 81(1):84-92

Schorb E, Kasenda B, Atta J, Kaun S, Morgner A, Hess G, Elter T, von Bubnoff N, Dreyling M, Ringhoffer M, Krause SW, Derigs G, Klimm B, Niemann D, Fritsch K, Finke J, Illerhaus G:
Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation. Haematologica 2013 May; 98(5):765-70

Kasenda B, Haug V, Schorb E, Fritsch K, Finke J, Mix M, Hader C, Weber WA, Illerhaus G, Meyer PT:
18F-FDG PET is an independent outcome predictor in primary central nervous system lymphoma. J Nucl Med. 2013 Feb; 54(2):184-91

Korfel A, Elter T, Thiel E, Hänel M, Möhle R, Schroers R, Reiser M, Dreyling M, Eucker J, Scholz C, Metzner B, Röth A, Birkmann J, Schlegel U, Martus P, Illerhaus G, Fischer L:
Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. Haematologica 2013 Mar; 98(3):364-70

Bergner N, Monsef I, Illerhaus G, Engert A, Skoetz N:
Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL). Cochrane Database Syst Rev. 2012 Nov 14; Review

Bromberg JE, Doorduijn JK, Illerhaus G, Jahnke K, Korfel A, Fischer L, Fritsch K, Kuittinen O, Issa S, van Montfort C, van den Bent MJ:
Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation - an International Primary Central Nervous System Lymphoma Study Group project. Haematologica 2013 May; 98(5):808-13

Stein A, Glockzin G, Wienke A, Arnold D, Edelmann T, Hildebrandt B, Hollerbach S, Illerhaus G, Königsrainer A, Richter M, Schlitt HJ, Schmoll HJ:
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. BMC Cancer 2012 Aug 16; Review

Buchkapitel:
Verschiedene Buchkapitel in: Das Rote Buch, Hämatologie und Internistische Onkologie. Ecomed-Verlag, 5th edition; Onkologie, Ecomed-Verlag, 4th edition